O	O	O	0	7	Danazol	Danazol	B-NP	NN	O	2	SUB	O
O	O	O	8	17	decreases	decrease	B-VP	VBZ	O	0	ROOT	O
O	O	O	18	31	transcription	transcription	B-NP	NN	O	2	OBJ	O
O	O	O	32	34	of	of	B-PP	IN	O	3	NMOD	O
T1	B-Protein	B-Protein	35	43	estrogen	estrogen	B-NP	NN	B-DNA	7	NMOD	B-DNA
T1	I-Protein	I-Protein	44	52	receptor	receptor	I-NP	NN	I-DNA	7	NMOD	I-DNA
O	O	O	53	57	gene	gene	I-NP	NN	I-DNA	4	PMOD	I-DNA
O	O	O	58	60	in	in	B-PP	IN	O	3	NMOD	O
O	O	O	61	66	human	human	B-NP	JJ	B-cell_type	10	NMOD	B-cell_type
O	O	O	67	76	monocytes	monocyte	I-NP	NNS	I-cell_type	8	PMOD	I-cell_type
O	O	O	76	77	.	.	O	.	O	2	P	O

O	O	O	79	80	1	1	B-LST	LS	O	0	ROOT	O
O	O	O	80	81	.	.	O	.	O	1	P	O

O	O	O	82	96	Administration	Administration	B-NP	NN	O	8	SUB	O
O	O	O	97	99	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	100	107	danazol	danazol	B-NP	NN	O	2	PMOD	O
O	O	O	108	111	for	for	B-PP	IN	O	1	NMOD	O
O	O	O	112	116	over	over	B-NP	IN	O	7	NMOD	O
O	O	O	117	120	one	one	I-NP	CD	O	5	AMOD	O
O	O	O	121	126	month	month	I-NP	NN	O	4	PMOD	O
O	O	O	127	134	reduced	reduce	B-VP	VBD	O	0	ROOT	O
O	O	O	135	138	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	139	145	levels	level	I-NP	NNS	O	8	OBJ	O
O	O	O	146	148	of	of	B-PP	IN	O	10	NMOD	O
T2	B-Protein	B-Protein	149	157	estrogen	estrogen	B-NP	NN	B-protein	13	NMOD	B-protein
T2	I-Protein	I-Protein	158	166	receptor	receptor	I-NP	NN	I-protein	19	NMOD	I-protein
O	O	O	167	168	(	(	O	(	O	16	DEP	O
T3	B-Protein	B-Protein	168	170	ER	ER	B-NP	NN	B-protein	16	DEP	B-protein
O	O	O	170	171	)	)	O	)	O	13	NMOD	O
O	O	O	172	175	and	and	O	CC	O	19	NMOD	O
O	O	O	176	179	its	its	B-NP	PRP$	O	19	NMOD	O
O	O	O	180	184	mRNA	mRNA	I-NP	NN	B-RNA	11	PMOD	B-RNA
O	O	O	185	187	to	to	B-PP	TO	O	8	VMOD	O
O	O	O	188	201	approximately	approximately	B-NP	RB	O	25	NMOD	O
O	O	O	202	204	50	50	I-NP	CD	O	21	NMOD	O
O	O	O	205	208	and	and	I-NP	CC	O	21	NMOD	O
O	O	O	209	211	20	20	I-NP	CD	O	21	NMOD	O
O	O	O	211	212	%	%	I-NP	NN	O	20	PMOD	O
O	O	O	212	213	,	,	O	,	O	8	P	O
O	O	O	214	226	respectively	respectively	B-ADVP	RB	O	8	VMOD	O
O	O	O	227	229	in	in	B-PP	IN	O	8	VMOD	O
O	O	O	230	239	monocytes	monocyte	B-NP	NNS	B-cell_type	28	PMOD	B-cell_type
O	O	O	239	240	.	.	O	.	O	8	P	O

O	O	O	241	242	2	2	B-LST	LS	O	0	ROOT	O
O	O	O	242	243	.	.	O	.	O	1	P	O

O	O	O	244	251	Danazol	Danazol	B-NP	NN	O	2	SUB	O
O	O	O	252	255	did	do	B-VP	VBD	O	0	ROOT	O
O	O	O	256	259	not	not	I-VP	RB	O	2	VMOD	O
O	O	O	260	265	alter	alter	I-VP	VB	O	2	VC	O
O	O	O	266	269	the	the	B-NP	DT	O	7	NMOD	O
O	O	O	270	281	degradation	degradation	I-NP	NN	O	7	NMOD	O
O	O	O	282	286	rate	rate	I-NP	NN	O	4	OBJ	O
O	O	O	287	289	of	of	B-PP	IN	O	7	NMOD	O
T4	B-Protein	B-Protein	290	292	ER	ER	B-NP	NN	B-RNA	10	NMOD	B-RNA
O	O	O	293	297	mRNA	mRNA	I-NP	NN	I-RNA	8	PMOD	I-RNA
O	O	O	298	300	in	in	B-PP	IN	O	7	NMOD	O
O	O	O	301	310	monocytes	monocyte	B-NP	NNS	B-cell_type	11	PMOD	B-cell_type
O	O	O	310	311	.	.	O	.	O	2	P	O

O	O	O	312	313	3	3	B-LST	LS	O	0	ROOT	O
O	O	O	313	314	.	.	O	.	O	1	P	O

O	O	O	315	322	Danazol	Danazol	B-NP	NN	O	2	SUB	O
O	O	O	323	332	decreased	decrease	B-VP	VBD	O	0	ROOT	O
O	O	O	333	336	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	337	350	transcription	transcription	I-NP	NN	O	5	NMOD	O
O	O	O	351	355	rate	rate	I-NP	NN	O	2	OBJ	O
O	O	O	356	358	of	of	B-PP	IN	O	5	NMOD	O
T5	B-Protein	B-Protein	359	361	ER	ER	B-NP	NN	B-DNA	8	NMOD	B-DNA
O	O	O	362	366	gene	gene	I-NP	NN	I-DNA	6	PMOD	I-DNA
O	O	O	367	369	to	to	B-PP	TO	O	2	VMOD	O
O	O	O	370	383	approximately	approximately	B-NP	RB	O	12	NMOD	O
O	O	O	384	386	50	50	I-NP	CD	O	10	AMOD	O
O	O	O	386	387	%	%	I-NP	NN	O	9	PMOD	O
O	O	O	388	390	in	in	B-PP	IN	O	2	VMOD	O
O	O	O	391	400	monocytes	monocyte	B-NP	NNS	B-cell_type	13	PMOD	B-cell_type
O	O	O	401	403	in	in	B-PP	IN	O	2	VMOD	O
O	O	O	404	405	a	a	B-NP	DT	O	17	NMOD	O
O	O	O	406	409	run	run	I-NP	NN	O	15	PMOD	O
O	O	O	409	410	-	-	B-ADVP	HYPH	O	2	VMOD	O
O	O	O	410	412	on	on	B-PP	IN	O	18	AMOD	O
O	O	O	413	418	assay	assay	B-NP	NN	O	19	PMOD	O
O	O	O	418	419	.	.	O	.	O	2	P	O

O	O	O	420	421	4	4	B-LST	LS	O	0	ROOT	O
O	O	O	421	422	.	.	O	.	O	1	P	O

O	O	O	423	430	Danazol	Danazol	B-NP	NN	O	2	SUB	O
O	O	O	431	434	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	435	442	release	release	I-VP	VB	O	2	VC	O
O	O	O	443	451	estrogen	estrogen	B-NP	NN	O	5	NMOD	O
O	O	O	452	464	predominance	predominance	I-NP	NN	O	3	OBJ	O
O	O	O	465	468	via	via	B-PP	IN	O	3	VMOD	O
O	O	O	469	472	the	the	B-NP	DT	O	8	NMOD	O
O	O	O	473	482	reduction	reduction	I-NP	NN	O	6	PMOD	O
O	O	O	483	485	of	of	B-PP	IN	O	8	NMOD	O
O	O	O	486	499	transcription	transcription	B-NP	NN	O	9	PMOD	O
O	O	O	500	503	for	for	B-PP	IN	O	10	NMOD	O
T6	B-Protein	B-Protein	504	506	ER	ER	B-NP	NN	B-DNA	13	NMOD	B-DNA
O	O	O	507	511	gene	gene	I-NP	NN	I-DNA	11	PMOD	I-DNA
O	O	O	511	512	,	,	O	,	O	2	P	O
O	O	O	513	518	which	which	B-NP	WDT	O	2	VMOD	O
O	O	O	519	524	leads	lead	B-VP	VBZ	O	15	SBAR	O
O	O	O	525	527	to	to	B-PP	TO	O	16	VMOD	O
O	O	O	528	531	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	532	541	reduction	reduction	I-NP	NN	O	17	PMOD	O
O	O	O	542	544	of	of	B-PP	IN	O	19	NMOD	O
T7	B-Protein	B-Protein	545	547	ER	ER	B-NP	NN	B-RNA	22	NMOD	B-RNA
O	O	O	548	552	mRNA	mRNA	I-NP	NN	I-RNA	25	NMOD	I-RNA
O	O	O	553	556	and	and	I-NP	CC	O	25	NMOD	O
T8	B-Protein	B-Protein	557	559	ER	ER	I-NP	NN	B-protein	25	NMOD	B-protein
O	O	O	560	571	expressions	expression	I-NP	NNS	O	20	PMOD	O
O	O	O	572	574	in	in	B-PP	IN	O	19	NMOD	O
O	O	O	575	584	monocytes	monocyte	B-NP	NNS	B-cell_type	26	PMOD	B-cell_type
O	O	O	584	585	.	.	O	.	O	2	P	O
